EMA — authorised 27 September 2004
- Application: EMEA/H/C/000557
- Marketing authorisation holder: sanofi-aventis Deutschland GmbH
- Local brand name: Apidra
- Indication: Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required.
- Status: approved